Summary: The new GOLD Report 2018 drew attention to the precise analysis of the historic number of exacerbations of COPD and stressed the importance of their severity. The GOLD standards recommend the use of long-acting bronchodilators in clinical categories B, C and D. In connection with the maintenance of the key role of chronic double bronchodilatation by the GOLD Guidelines as the most important treatment in stable COPD, it should be emphasized that it is the most effective symptom-oriented therapy with additional value reducing the risk of COPD exacerbations. In the context of dual bronchodilatation, the results of some clinical trials evaluating the efficacy and safety of the preparations umeclidinium (umeclidinium bromide) + vilanterol, olodaterol + tiotropium (tiotropium bromide) and glycopyrronium (glycopyrronium bromide) + indacaterol, should be better known. The medicine combinations of LAMA and LABA presented in the article, involving the use of modern chemical molecules, are another important clinical tool in the hands of practitioners.